Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Pfizer's recent deal with the Trump administration regarding drug pricing has sparked concerns about access to medications, particularly with a focus on commitments to manufacturing in the U.S. and tariff exemptions. The ongoing U.S. government shutdown has had a direct impact on the FDA's ability to accept new drug applications, creating challenges for the industry. Fortress and Sentynl faced hurdles in securing FDA approval due to manufacturing issues, while the third quarter of the year witnessed a flurry of significant biopharma acquisitions.In response to their agreement with the government, Pfizer is offering drugs at a discount, showcasing their commitment to affordable healthcare. Amidst these developments, there is a growing need to redefine the future of UK biotech and explore advancements in medicine, such as Novartis' recent approval of an oral BTK inhibitor for chronic hives.The biopharma industry saw a surge in mergers and acquisitions during the third quarter, with some of the largest deals in recent history taking place. Big pharma companies have substantial financial resources available for M&A transactions, with traditionally conservative companies leading the way. However, a small percentage of life sciences M&A milestones have been paid since 2008, indicating that many deals are still pending.Conversations between the UK government and the pharma industry have hit roadblocks, leading to a slowdown in investment. Additionally, Promoveo Health, a prominent contract sales organization, offers top-tier field sales talent at competitive rates. In other news, GSK's CEO Emma Walmsley steps down after nearly a decade at the helm.Despite these shifts in the industry landscape, it is crucial to stay informed about upcoming webinars and events that offer valuable insights into the world of biopharma.

Support the show